• Users Online: 32
  • Print this page
  • Email this page
Year : 2018  |  Volume : 1  |  Issue : 1  |  Page : 3-8

Dual antiplatelet therapy after percutaneous coronary intervention and stenting: Customize your approach

1 Department of Cardiology, Medanta-The Medicity, Gurgaon, Haryana, India
2 Department of Cardiology, Virinchi Hospital, Indo-US Super Speciality Hospital, Hyderabad, Telangana, India

Correspondence Address:
Dr. Gagandeep S Wander
Department of Cardiology, Medanta-The Medicity, Sector 38, Gurgaon, Haryana 122011
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/IHJI.IHJI_18_18

Get Permissions

Dual antiplatelet therapy (DAPT), defined as a combination of aspirin with one other oral antiplatelet agent (among clopidogrel, prasugrel, and ticagrelor), has become an essential component of pharmacological management of patients who have undergone a percutaneous coronary intervention (PCI). Over the last few years, a vast amount of information has become available about the appropriate indications, choice, and duration of DAPT following PCI in different patient subsets. This review summarizes these evidences and provides a practical guidance for the selection of appropriate DAPT in different clinical settings.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded186    
    Comments [Add]    

Recommend this journal